Reply  by Taylor, Spence M.
LETTERS TO THE EDITOR
Regarding “Transcervical carotid stenting with
carotid artery flow reversal: 3-year follow-up of 103
stents”
We read with interest the paper by Criado et al1 and were
impressed with their innovative approach to intervention for ca-
rotid disease. However, a number of difficulties were highlighted
at our recent journal club review of the study.
First, the authors advocate their method as suitable for pa-
tients at high risk for general anesthesia. Carotid endarterectomy is
routinely performed under local anesthesia in many centers, and
95% of all carotid endarterectomies in our institution are per-
formed successfully under local anesthesia compared with 70%
reported in this series.
Second, although the authors present an impressive series with
a low stroke rate, their method is still associated with a considerable
rate of presumably embolic transient neurologic events (transient
ischemic attacks and unresponsive episodes) in this low-risk group
(64% asymptomatic). This is particularly disappointing because the
authors advocate their technique on the basis of a reduction of
periprocedural embolization. In this context, for the reported
series to demonstrate any advantage over standard protection
devices, some form of imaging or Doppler studies, or both, would
have been necessary.
Finally, no comparison with previous studies was made for the
non-neurologic complications. We were particularly alarmed by 24
patients (23%) developing bradycardia or hypotension (2 with
asystole) requiring pharmacologic intervention.
We agree that further investigation of alternative techniques
and technologies are required to improve the results of carotid
stenting. However, to conclude that this technique compares
favorably with stenting using distal filter protection is premature
on the basis of this series, which further emphasizes the difficulties
and complexities of carotid intervention.
Ian D. Hunter, MBBS, MRCS
Michael A. Murphy, MD, FRCS
Department of Vascular Surgery
John Radcliffe Hospital
Oxford, United Kingdom
REFERENCE
1. Criado E, Fontcuberta J, Orgaz A, Flores A, Doblas M. Transcervical
carotid stenting with carotid artery flow reversal: 3-year follow-up of 103
stents. J Vasc Surg 2007;46:864-9.
doi:10.1016/j.jvs.2007.11.070
The authors declined to reply to this letter.
–Eds.
Regarding “A comparison of percutaneous
transluminal angioplasty versus amputation for
critical limb ischemia in patients unsuitable for
open surgery”
In the article by Taylor et al,1 the authors reported that almost
70% of the patient population described in their study was affected
by diabetes. We were rather surprised by the high percentage of
amputations in the case histories (700/2400, 29.2%), as well as by
the high percentage of the 30-day mortality in the group of
amputated patients and, most of all, in the peripheral transluminal
angioplasty (PTA) group. These data are quite in contrast with
data from our experience.2 This series consisted of very elderly
patients. The percentage of patients aged 80 years and older who
underwent PTA was almost the double of that of patients who
underwent amputation: 36.6% vs 21.8%.
We found the hypothesis that age can be the greatest prog-
nostic independent factor fascinating, although the model has
been adjusted for age, race, and diabetes mellitus. If this were true
and the model has been adjusted for age, race, and diabetes
mellitus, these data would hardly seem to meet the criteria for
compliance to “good clinical practice” and, consequently, we
believe that the authors’ conclusions would hardly be acceptable.
Ezio Faglia, MD
Giacomo Clerici, MD
IRCCS Policlinico Multimedica
Milan, Italy
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Reply
This letter is written in response to both the Invited Commen-
tary by Joseph L. Mills, MD and a recent letter sent to the Journal
concerning our article entitled “A comparison of percutaneous
transluminal angioplasty versus amputation for critical limb isch-
emia in patients unsuitable for open surgery”.1 In this article, we
attempted to address the utility of percutaneous transluminal
angioplasty in chronically ill patients with critical limb ischemia
who, because of their overall medical condition, were not candi-
dates for open bypass. Our retrospective cohort comparison found
that amputation yielded similar functional outcomes at 1 year and
better overall survival outcomes than angioplasty. Based on this,
we concluded angioplasty is probably not beneficial. Apparently,
our conclusions have not been universally accepted. At present it
seems our critics believe we have unfairly maligned angioplasty and
have cited the heterogeneity of our cohort groups as the primary
reason.
By way of background, we originally examined the 131 pa-
tients who underwent percutaneous transluminal angioplasty
(PTA) for limb salvage alone, and found our results to be both
bland and inconclusive (63% 12 month limb salvage, 29% survival
at 24 months, 60.2% maintenance of ambulation at 24 months,
and 60.5% maintenance of independent living status at 24
months). Therefore, as a general reference for comparison, we
examined all amputees who met our definition of “unsuitable for
surgery” during the same time period. (Please note, our amputa-
tion registry includes all patients amputated, not just patients
amputated who failed revascularization as incorrectly assumed by
our critics). Indeed, heterogeneity of demographics between the
two groups was notable. However, when adjusting for age, race,
897
diabetes, prior vascular invention, dementia, and baseline func-
tional status, we found “type of treatment” to be the most consis-
tent independent predictor of outcome. While we acknowledge
that our comparison does not represent the purity of a randomized
prospective trial, we likewise believe it to be inappropriate to
completely dismiss our valid statistical evidence.
Interestingly, our critics have chosen to quibble about our
interpretation of the findings, taking a more optimistic, “glass
half-full” not “glass half-empty” view toward the angioplasty co-
hort. Perhaps they are correct. But in the end, does it really matter?
If quibbling is required to rationalize the superiority of revascular-
ization over the gold standard of treatment failure (ie, limb ampu-
tation), then we all are truly “missing the forest for the trees”.
Perhaps we need to accept that sometimes outcome is influenced
more by the deteriorating health of the patient than by the treat-
ment modality employed.
In our financially failing health system where the rationing of
care for the greater good is inevitable, we simply can not afford to
devote endless resources for unproven therapies. In that light, if a
patient is too chronically ill to realize the physical benefit of limb
salvage, maybe it’s time to “throw in the towel”.
Spence M. Taylor, MD
Greenville Hospital System
Greenville, SC
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Regarding “Bare metal stent infections: Case report
and review of the literature”
We read with interest the report byHogg et al1 describing two
case reports with bare metal stent infections and reviewing the
literature. It is known that there are no standards for managing
bare metal stent infections. Therefore, it is important that every
new, uncommon, or difficult case is reported. Last year,2 we
reported an interesting case of stent infection by mucormycosis in
a renal transplant patient, which was not included in the literature
review by Hogg et al.1
Our report pointed out some interesting data regarding infec-
tious complications following placement of bare metal stents in the
external iliac artery. Indeed, it is the only report with fugal infec-
tion by mucormycosis, which has a predilection for vascular inva-
sion causing thrombosis and infraction/tissue necrosis. This type
of infection typically occurs in immunocompromised and diabetic
patient. Interestingly, fugal infection by mucormycosis occurred
while our patient was under prophylactic antibiotic therapy (van-
comycin). The majority of reports regarding complications after
percutaneous stenting involve the access site. Moreover, although
in the majority of cases the symptoms were presented few days after
the stent placement, in our case they were presented after 2months
in the form of septic microembolism. Notably, two novel risk
factors for stent infections that can be suggested by our report are:
the previous surgery in the artery in which the stent was placed
and the immunocompromised patients. Finally, in our report the
patient was treated by surgical stent resection, proximal-distal
ligation of the infected external iliac artery, and femoral-femoral
autologous vein by pass followed by intravenous therapy with
amphotericin B for 3 months. One year later the patient was free
from any symptoms and without recurrence of the mucormycosis.
In conclusion, we suggest that our report add new data
regarding the above mentioned severe complication, and mucor-
mycosis infection should be considered as a potential threat for
bare metal stent insertion particularly in immunosuppressed pa-
tients.
John K. Bellos, MD
Marios Moustardas, MD
Christos D. Liapis, Prof., FRCS
Laiko Hospital
Athens, Greece
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We appreciate the interest in our report and the comments
provided by Drs Bellos, Moustardes, and Liapis regarding our
review. The comments in their Letter to the Editor and the
published case report by Liapis et al1 regarding the importance of
reporting cases of stent infections, antibiotic prophylaxis, and
aggressive surgical and antibiotic therapy, mirror our own practice
and sentiments. Over the past few years, we have been tracking
stent infections that we have treated at our institution and found
four total bare metal stent infections. Our published case report
only includes two of these infections.2 Of the unreported cases,
one patient presented with a simultaneous prosthetic graft infec-
tion in addition to the bare metal stent infection, while the other
patient presented with a concomitant infection of a prosthetic
aortic endograft. Both of these cases were treated with resection,
radical surgical debridement, and revascularization. We excluded
these two reports from our publication because we believed it was
impossible to determine which infection occurred first: the pros-
thetic graft material or the bare metal stent. Our intention was to
publish a report highlighting cases of isolated bare metal stent
infections.
When preparing our report, we read your publication with
great interest.1 However, similar to the cases we excluded, we
believed your case was unique from the majority of the cases we
included in our review. You described a patient that (1) had
undergone previous arterial surgery within months of the periph-
eral artery stent deployment, (2) had recent treatment with antire-
jection therapy, and (3) had the possibility of an existing infection
at the time of the stent deployment. For these reasons we felt your
report, while very interesting and important, was distinctly differ-
ent from the typical angioplasty and stent procedures we included
in our review, as your patient had several known risk factors to
develop a bare metal stent infection at the time of stent deploy-
ment.
However, your point about mucormycosis is important and
worth reiterating. While reports exist of fungal infections in arterial
grafts,3 aortic endografts,4 and covered stents,5 your report 1 is the
only one we identified with a fungal, not bacterial, bare metal stent
infection. Given that no consensus has been reached regarding the
optimal management of bare metal stent infections, our institution
advocates prompt, radical debridement, and revascularization.
But, your report makes a strong argument to consider the patho-
logic organism, specifically mucormycosis, when devising a treat-
ment strategy. Several of the reports sited in our review did not
treat patients with a surgical approach: four of these 11 patients
died, two of these 11 appeared to have no adverse sequelae, and
five had to be followed closely due to pseudoaneurysm formation
or stent thrombosis.2 Given the pathophysiology and virulence of
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